Trial results

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

NCT07834398 on ClinicalTrials.gov · last registry update 2026-09-22

A small phase 3 — 150 participants, against a typical 424. The sponsor logged completion for 13 April 2026. Primary outcome, as filed: change in body weight at 3 and 6 months. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Zagazig University

Sponsor type

Other Gov

Enrollment

150

Started

2025-11-14

Primary completion

2026-04-13 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

change in body weight at 3 and 6 months

Conditions studied

Non-diabetec Obesity · Obesity (Disorder)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.